Interestingly, despite its oncogenic potential, inactivating mutations involving TGF-β pathway components are surprisingly rare in hematopoietic malignancies with only a few instances reported, such as TGFβRII mutations in T-ALL (56, 57). Here, TGFB1 is linked to acute lymphoblastic leukemia.